Figure 3.

Development of an immune-competent syngeneic tumor model for CVA21 interventions and treatment study design. (A) Immunoblot of isogenic clones of YUMM 2.1 cells transduced with a lentivirus expressing ICAM-1 and selected with puromycin. GAPDH was used as a loading control. YUMM 2.1 cells transfected with pDest 12.2 ICAM-1 expression vector and YUMM 2.1 parental cells were used for positive and negative controls, respectively (A,B). (B) Immunoblot and images of YUMM 2.1 ICAM-1 tumors grown in the flank of C57BL6 mice. (C) Treatment study design.